Searching…
Abstract Background Terminal erythropoiesis is a complex multistep process involving coordination of gene transcription and dramatic nuclear condensation, which leads to the expulsion of nuclei to generate reticulocyt...
Background Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic fea...
Created Date 10/11/2015 5:15:48 AM
https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-4-43 https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-4-45 https://jhoonline ...
Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducted this m...
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01737-8 https://jhoonline.biomedcentral.com/articles/10.1186/s13045-025-01735-w https://jhoonline ...
https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-3-6 https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-3-5 https://jhoonline.biomedcentral ...
As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remai...
jhoonline.biomedcentral.com
jhoonline.biomedcentral.com
